SMS alerts to reduce toxicity and improve treatment compliance in cancer chemotherapy: A clinical trial
- Conditions
- Health Condition 1: C169- Malignant neoplasm of stomach, unspecifiedHealth Condition 2: null- Stomach and Colorectal cancer patients on chemotherapy
- Registration Number
- CTRI/2015/02/005491
- Lead Sponsor
- Tata Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Provide informed consent and sign the patient information sheet
- Own a mobile phone with text message (SMS) facility.
- Diagnosed with stomach cancer (all histological types) and are planned for peri-operative chemotherapy (before surgery) with EOX protocol i.e. combination of Epirubicin, Oxaliplatin and Capecitabine given every 3 weeks.
- Diagnosed with colorectal cancer (post-surgery and/or radiotherapy, including metastatic disease) and planned to start on adjuvant or palliative chemotherapy with CapOx protocol i.e. combination of Capecitabine and Oxaliplatin given every 3 weeks.
- Residing within 50km radius of TMC.
- Patient or any of his/her immediate family member(s) who are able to read and comprehend text message in English
- Not a citizen of India e.g. patients from neighbouring countries like Bangladesh, Nepal, Bhutan.
- Non-resident Indians i.e. Indians residing outside India but visiting India for cancer treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Number of Suspected Unexpected Serious Adverse Reactions (SUSARs) <br/ ><br>- Number of delayed chemotherapy cycles due to toxicity <br/ ><br>- Number of dose reductions due to severe toxicity <br/ ><br>Timepoint: NA
- Secondary Outcome Measures
Name Time Method - Overall cost of treatment and out of pocket expenditureTimepoint: NA